Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

  High throughput screening models for intracellular delivery of antimicrobial nanotherapeutics


   School of Pharmacy

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Dr Justin Tian, Prof Brendan Gilmore, Prof William Hope  Applications accepted all year round  Self-Funded PhD Students Only

About the Project

Fungal and bacterial infections contribute to over 7 million deaths yearly, affecting over 300 million people globally (GAFFI). Since many antimicrobial drugs are ancient, we are witnessing an unprecedented rise in the emergence of pathogenic resistance to the commonly used antimicrobial drugs (Fisher et al., Nat.Rev.Micro.2022). 

Nanomedicine, the use of nanotechnology in developing new medicines, is recognised as one of the Key Enabling Technologies, promising new and innovative solutions to address antimicrobial resistance. Nanocarrier-encapsulated antimicrobial drugs can lower the required dose, enhance the efficacy of the treatment through intracellular delivery, and reduce the chances of antimicrobial drug resistance. Despite these potential benefits, applying a nanoparticle-based drug delivery system requires precise control over the size, drug encapsulation, and a robust production method at commercially practical scales.

Research groups at SoP have been leading the development of a new interdisciplinary research area, the interfaces between design, screening, and scale-up production of antimicrobial nanotherapeutics. The perspective PhD students will work within this dynamic team to develop new high throughput screening (HTS) models for in vitro/ex-vivo selection of antimicrobial nanocarriers.

The students will work with the PDRAs of the recently established EnLAmB network (MRC project MR/X014010/1), linking with the Centre of Excellence in Infectious Diseases Research at the University of Liverpool (THE LANCET Infectious Diseases, 2021).

Expected Impact Activities:

1.      New HTS models for intracellular delivery can provide proof-of-concept for new grant applications, BBRSC or EPSRC.

2.      Advances in scalable nano-therapeutical manufacturing can attract new privately funded projects from the industry, CATCH.

3. New antimicrobial nanotherapeutics can lead to new treatments and interventions, iREACH.

Home applicants must meet the following academic criteria:

1st or 2.1 honours degree in a relevant subject. Relevant subjects include Pharmacy, Pharmaceutical Sciences, Biochemistry, Biological/Biomedical Sciences, Chemistry, Engineering, or a closely related discipline.

International applicants must meet the following academic criteria:

IELTS (or equivalent) of 7.0, a 2.1 honours degree (or equivalent) and a master’s degree in a relevant subject.

Applicants should apply through the University's Direct Application Portal: https://dap.qub.ac.uk/portal/user/u_login.php


Biological Sciences (4) Chemistry (6) Engineering (12) Medicine (26)
Search Suggestions
Search suggestions

Based on your current searches we recommend the following search filters.

 About the Project